Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576398 | 0.85 | CA12 (0.41) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL5352724 | 0.84 | — | — | |
| SCHEMBL7706827 | 0.83 | CA1 (0.50) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL9117953 | 0.80 | HSP90AA1 (0.30) | HSP90AA1HSP90AB1 | |
| SCHEMBL3182564 | 0.78 | CA12 (0.46) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL1793777 | 0.78 | PREP (0.44) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL4004898 | 0.77 | CYP3A4 (0.47) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL232409 | 0.77 | CA12 (0.45) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL2329760 | 0.77 | ACHE (0.50) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL5292779 | 0.77 | ACHE (0.45) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2023-12-07 | — | — | US | disclosed |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | DMK PHARMACEUTICALS CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220226312-A1 | OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11246865-B2 | Opioid for use to reduce and/or treat drug addiction | VERSI GROUP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2021-07-22 | — | — | US | disclosed |
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | VERSI GROUP, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200121674-A1 | AN OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2019-02-07 | — | — | US | disclosed |
| EP-3436013-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Versi Group, LLC (US) | 2019-02-06 | — | — | EP | disclosed |
| WO-2018204163-A1 | AN OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | VERSI GROUP, LLC (US) | 2018-11-08 | — | — | WO | disclosed |
| US-6514975-B1 | Tetrazoles as selective agonists for the delta opioid receptor | PFIZER INC | 2003-02-04 | — | — | US | disclosed |
| EP-0914319-B1 | DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | TEIJIN LTD (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-6200978-B1 | FOR PREVENTING OR TREATING INFLAMMATORY DISEASES SUCH AS ARTHRITIS, PSORIASIS, ASTHMA, OR INFLAMMATORY BOWEL DISEASE, DISORDERS OF RESPIRATORY FUNCTION, GASTROINTESTINAL DISORDERS SUCH AS FUNCTIONAL BOWEL DISEASE, AS ANALGESICS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
| EP-0983251-A1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | Pfizer Limited (GB) | 2000-03-08 | — | — | EP | disclosed |
| US-5998442-A | ANTICHOLESTEROL AGENTS | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0914319-A1 | DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | TEIJIN LIMITED (JP) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998052929-A1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | PFIZER LIMITED (GB) | 1998-11-26 | — | — | WO | disclosed |
| EP-0826683-A1 | Benzo[B]thiophene compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1997044329-A1 | DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | TEIJIN LIMITED (JP) | 1997-11-27 | — | — | WO | disclosed |
| EP-0271287-A2 | Quinoline dioic acids and amides | MERCK FROSST CANADA INC. (CA) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121674-A1 | AN OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | CA12 4369/4885CA1 4210/4885CA9 4605/4885 |
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | OPRD1, OPRK1, OPRM1 | CA12 3462/4885CA1 2379/4885CA9 4007/4885 |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | CA12 4400/4885CA1 4143/4885CA9 4681/4885 |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | CA12 3462/4885CA1 2379/4885CA9 4007/4885 |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | CA12 4536/4885CA1 4205/4885CA9 4732/4885 |
| US-20220226312-A1 | OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | CA12 4400/4885CA1 4143/4885CA9 4681/4885 |
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | CA12 3709/4885CA1 2641/4885CA9 4145/4885 |
| US-11246865-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | CA12 4400/4885CA1 4143/4885CA9 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.